Great news with the patent being granted & very timely....
Firstly intracellular targets are the key point of Roches partnership & they are currently in discussion regarding the next stage of the agreement.
Secondly it's a very nice bit of paper to be holding heading into BioTrinity UK which is underway this week with all of the Top10 Global Pharmaceutical companies present.
"As more is known about the molecular mechanisms inside cells that cause disease, the pharmaceutical industry is increasingly interested in sourcing drug candidates that can target these intracellular pathways. Traditionaly, protein interactions inside cells have been very hard to block, but this patented screening technology is idealy suited for rapid indentification of Phylomer drug candidates against such targets."
PYC Price at posting:
6.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)